The research firm’s previous quarterly report in February called attention to continued supply chain and labor problems for medtech.
The report flagged legislative proposals for new rules and regulations on medical device developers and manufacturers, including new cybsecurity rules.
Moody’s also warned of the credit risk of regulation on contract manufacturing organizations (CMOs), given that oversight can be opaque because the FDA does not regulate all CMOs.